Sheila Singh - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Member, McMaster Stem Cell and Cancer Research Institute (SCC-RI), Faculty of Health Sciences
Director, Centre for Discovery in Cancer Research (CDCR), Faculty of Health Sciences
Associate Member, Biochemistry & Biomedical Sciences, Faculty of Health Sciences
Professor, Surgery, Faculty of Health Sciences
Canada Research Chair in Human Cancer Stem Cell Biology, McMaster University,

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Research
Teaching
Background
Contact
View All

selected scholarly activity

books
- Preface. Ed. 1869. 2019
chapters
- Cancer Stem Cells: Current Challenges and Future Perspectives. Methods in molecular biology (Clifton, N.J.). 1-18. 2024
- Childhood Medulloblastoma: An Overview. Methods in molecular biology (Clifton, N.J.). 1-12. 2022
- Intratumoral heterogeneity associated with glioblastoma drug response and resistance. 185-199. 2021
- Brain Tumor Stem Cells Methods and Protocols Preface. Methods in molecular biology (Clifton, N.J.). V-V. 2019
- Detecting Stem Cell Marker Expression Using the NanoString nCounter System. Methods in molecular biology (Clifton, N.J.). 57-67. 2019
- Differentiation of Brain Tumor Initiating Cells. Methods in molecular biology (Clifton, N.J.). 85-91. 2019
- Flow Cytometric Analysis of Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 69-77. 2019
- In Vitro Assays for Screening Small Molecules. Methods in molecular biology (Clifton, N.J.). 189-196. 2019
- In Vitro Self-Renewal Assays for Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 79-84. 2019
- In Vivo Murine Models of Brain Metastasis. Methods in molecular biology (Clifton, N.J.). 231-238. 2019
- Introduction to Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 1-9. 2019
- Introduction to Cancer Stem Cells: Past, Present, and Future. Methods in molecular biology (Clifton, N.J.). 1-16. 2018
- Introduction to Cancer Stem Cells: Past, Present, and Future (vol 1692, pg 1, 2018). Methods in molecular biology (Clifton, N.J.). E1-E1. 2018
- Giant Cell Tumor. 1896-1901. 2016
- Flow cytometric identification and characterization of neural brain tumor initiating cells for pathophysiological study and biomedical applications.. 199-212. 2015
- Isolation and identification of neural cancer stem/progenitor cells.. 145-168. 2015
- Cancer stem cells in pediatric brain tumors. 2015
- Chapter 17 Flow-Cytometric Identification and Characterization of Neural Brain Tumor-Initiating Cells for Pathophysiological Study and Biomedical Applications. 199-211. 2015
- Glioblastoma Stem Cells Drive Tumor Recurrence and Patient Relapse: What's the Evidence?. 193-208. 2014
- Cancer Genomics Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2014
- Chapter 19 Brain Tumor Genomics Sequencing to Clinical Utility. 321-338. 2014
- The Brain Tumor Genome: A Comprehensive Review 2014
- Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2013
- Giant Cell Tumor. 1-5. 2012
- Neurosurgical management of brain tumours. 2012
- Origins of Metastasis-Initiating Cells. 229-246. 2012
- Cancer Stem Cells in Brain Cancer. 37-56. 2011
- Chapter 75 Supratentorial Low-Grade Gliomas. 572-578. 2005
- Supratentorial Low-Grade Gliomas. 572-578. 2005
conferences
- IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 2023
- 852 Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. Journal for ImmunoTherapy of Cancer. A891-A891. 2022
- DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. Neuro-Oncology. 98-99. 2022
- DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY. Neuro-Oncology. 291-292. 2022
- ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA. Neuro-Oncology. 228-228. 2022
- NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA.. Neuro-Oncology. 117-117. 2022
- Preclinical development of CD133 targeted immunoPET probes. Nuclear Medicine and Biology. S19-S20. 2022
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Reports. 111420-111420. 2022
- Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma. Cancer Research. 2022
- HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases. Cancer Research. 2022
- Interrogating the pre-metastastic gene signature to block brain metastases. Cancer Research. 2022
- Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer. Cancer Research. 2022
- AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 215-215. 2021
- ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. Neuro-Oncology. 175-175. 2021
- FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 22-22. 2021
- THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 21-21. 2021
- Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models.. Cancer Research. 2021
- EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. i10-i10. 2021
- EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. Neuro-Oncology. i49-i49. 2021
- PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody. Journal of Nuclear Medicine. 2021
- Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma. Cancer immunology research. PO081-PO081. 2021
- Abstract PR009: The functional genomic landscape of recurrent glioblastoma. Cancer immunology research. PR009-PR009. 2021
- Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma.. Cancer immunology research. 2021
- The functional genomic landscape of recurrent glioblastoma.. Cancer immunology research. 2021
- The functional genomic landscape of recurrent glioblastoma.. Cancer immunology research. 2021
- 5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers. Annals of Oncology. S1419-S1419. 2020
- DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 399-399. 2020
- Identification of therapy driven events on proteome landscape of patient matched primary-recurrent Glioblastoma for development of novel diagnostic and predictive biomarkers. Clinical Biochemistry. 83-83. 2020
- IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 213-213. 2020
- TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 196-196. 2020
- LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 239-239. 2019
- Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence. Cancer Research. 2019
- Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence. Cancer Research. 3682-3682. 2019
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Cancer Research. 570-570. 2019
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Immunology. 570-570. 2019
- MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE. Neuro-Oncology. ii105-ii105. 2019
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 108-108. 2019
- MUSAShi-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 112-112. 2019
- SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 117-117. 2019
- BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 1702-1716. 2019
- A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 107-107. 2018
- DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 273-273. 2018
- MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 208-208. 2018
- Abstract 1140: Genes preserving stem cell state in group 3 medulloblastoma brain tumor initiating cells contribute to therapy evasion and relapse. Cancer Research. 1140-1140. 2018
- Abstract 148: Canonical Wnt activation as a therapeutic strategy in pediatric medulloblastoma. Cancer Research. 148-148. 2018
- Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies. Cancer Research. 1763-1763. 2018
- Abstract 1911: Uncovering novel targets of recurrent glioblastoma using transcriptomic profiling in a patient-derived xenograft model. Cancer Research. 1911-1911. 2018
- Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy. Cancer Research. 390-390. 2018
- Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases. Cancer Research. 44-44. 2018
- INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 133-133. 2018
- SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 119-119. 2018
- Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma. Journal of Clinical Oncology. 2018
- A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 54-54. 2017
- A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 72-72. 2017
- CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 229-229. 2017
- CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 255-255. 2017
- CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 230-230. 2017
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 255-255. 2017
- GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 234-235. 2017
- IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 254-254. 2017
- PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 49-49. 2017
- PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 46-46. 2017
- THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 113-113. 2017
- Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma. Cancer Research. 3639-3639. 2017
- Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma. Cancer Research. 3758-3758. 2017
- Abstract 3844: Identification and validation of novel therapeutic targets driving clonal heterogeneity in treatment-refractory GBM. Cancer Research. 3844-3844. 2017
- Abstract 3870: Clonal evolution of medulloblastoma BTICs in response to therapy. Cancer Research. 3870-3870. 2017
- Abstract 5831: Activated Wnt signaling for the treatment of recurrent medulloblastoma. Cancer Research. 5831-5831. 2017
- CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 58-58. 2017
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 44-44. 2017
- INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI, IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 43-43. 2017
- Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis. Pancreas. 446-446. 2017
- Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Cancer immunology research. B079-B079. 2016
- Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. Cancer immunology research. B092-B092. 2016
- CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 214-215. 2016
- CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 214-214. 2016
- DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. Neuro-Oncology. 211-212. 2016
- Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. Neuro-Oncology. 207-207. 2016
- THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 98-98. 2016
- Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells. Cancer Research. 1481-1481. 2016
- Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors. Cancer Research. 2300-2300. 2016
- Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma. Cancer Research. 2512-2512. 2016
- Abstract 2680: Development and application of a novel model of human lung-to-brain metastasis: identification of TWIST2 and SPOCK1 as unique regulators of brain metastases. Cancer Research. 2680-2680. 2016
- A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS. Neuro-Oncology. 149-149. 2016
- ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 101-101. 2016
- DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. Neuro-Oncology. 40-40. 2016
- IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?. Neuro-Oncology. 150-150. 2016
- MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. Neuro-Oncology. 16-16. 2016
- Activated Wnt signaling for the therapeutic targeting of treatment-refractory medulloblastoma stem cells. Journal of Neurosurgery. A1153-A1153. 2016
- Bmi1 is a Therapeutic Target in Recurrent Medulloblastoma. Journal of Neurosurgery. A1204-A1205. 2016
- EARLY POST-OPERATIVE MRI FOLLOWING A RESECTION OF A PEDIATRIC BRAIN TUMOR - WHAT IS THE RIGHT TIMEPOINT?. Pediatric Blood and Cancer. S283-S283. 2015
- RADIATION NECROSIS IN CHILDREN - AN UNDERREPORTED PROBLEM?!. Pediatric Blood and Cancer. S282-S283. 2015
- ACTIVATED Wnt SIGNALING TARGETS Sox2+TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 23-23. 2015
- DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22-22. 2015
- An Open Label Randomized Control Pilot Study Examining the Use of Ibuprofen and Acetaminophen for Acute Headache in Post-Concussive Youth.. Journal of Head Trauma Rehabilitation. E116-E116. 2015
- RM-06 * IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. Neuro-Oncology. v187-v187. 2014
- SC-33 * POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. Neuro-Oncology. v204-v204. 2014
- GLIOMA SPECIFIC PEPTIDES: A PLATFORM FOR MOLECULAR IMAGING AND THERAPEUTIC TARGETING. Neuro-Oncology. iii37-iii37. 2014
- SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA. Neuro-Oncology. iii5-iii5. 2014
- PERSONALIZING THE TREATMENT OF PEDIATRIC MEDULLOBLASTOMA: POLO-LIKE KINASE 1 AS A MOLECULAR TARGET IN HIGH-RISK CHILDREN. Neuro-Oncology. 77-77. 2014
- Returning children and youth to activity and to school after MTBI/concussion: A conservative approach with new evidence-based guidelines. Brain Injury. 581-582. 2014
- Returning Children and Youth to Activity and to School after MTBI/Concussion: A Conservative Approach with New Evidence Based Guidelines. Journal of Head Trauma Rehabilitation. E38-E38. 2013
- Bmi1 REGULATES GLI ACETYLATION THROUGH CULLIN3 IN MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 43-43. 2013
- CLONAL EVOLUTION OF MEDULLOBLASTOMA BRAIN TUMOUR-INITIATING CELLS (BTICS) IN RESPONSE TO THERAPY: DISCOVERING THE REFRACTORY BTIC POPULATION. Neuro-Oncology. 27-27. 2013
- PERSONALIZING THE TREATMENT FOR MEDULLOBLASTOMA: POLO-LIKE KINASE 1 (PLK1) AS A MOLECULAR TARGET FOR THE SONIC HEDGEHOG (SHH) SUBTYPE. Neuro-Oncology. 2-3. 2013
- REGULATION OF MEDULLOBLASTOMA STEM CELL SELF-RENEWAL THROUGH THE DEVELOPMENTALLY CONSERVED FoxG1-Bmi1-p21 AXIS. Neuro-Oncology. 21-21. 2013
- Bmi1 AND FoxG1 REGULATE SELF-RENEWAL IN CD15+non-Shh/Wnt SUBTYPE MEDULLOBLASTOMA STEM CELLS THROUGH RECIPROCAL PROMOTER OCCUPANCY. Neuro-Oncology. 93-94. 2012
- Bmi1 REGULATION OF SONIC HEDGEHOG SIGNALING THROUGH THE E3 UBIQUITIN LIGASE CULLIN3 IN MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 94-94. 2012
- DEVELOPMENT OF IN VITRO AND IN VIVO CHEMO-AND RADIOTHERAPY MODELS FOR DETECTION OF TREATMENT-REFRACTORY MEDULLOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 94-94. 2012
- FRACTIONATED STEREOTACTIC RADIOSURGERY FOR RELAPSED PAEDIATRIC PRIMITIVE NEUROECTODERMAL TUMOURS: A SINGLE INSTITUTION EXPERIENCE. Neuro-Oncology. 146-146. 2012
- PEDIATRIC AND ADULT MEDULLOBLASTOMA: WHAT MAKES THE DIFFERENCE IN OUTCOME?. Neuro-Oncology. 86-86. 2012
- PEDIATRIC INTRACRANIAL GERMINOMA CASE SERIES: FOUR PATIENTS WITH ATYPICAL CLINICO-RADIOLOGICAL PRESENTATION. Neuro-Oncology. 54-54. 2012
- POLO-LIKE KINASE 1 (PLK1) INHIBITION KILLS GLIOBLASTOMA MULTIFORME BRAIN TUMOUR CELLS IN PART THROUGH LOSS OF SOX2 AND DELAYS TUMOUR PROGRESSION IN MICE. Neuro-Oncology. 67-67. 2012
- YB-1 BRIDGES NEURAL STEM CELLS AND BRAIN TUMOR-INITIATING CELLS VIA ITS ROLES IN DIFFERENTIATION AND CELL GROWTH. Neuro-Oncology. 14-15. 2012
- Combined Heart-Liver Transplant: An Analysis of Nearly 200 Adults Listed in the Modern Era. American Journal of Transplantation. 119-119. 2012
- Double Lung Transplant Improves Survival Compared with Single Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension.. American Journal of Transplantation. 49-49. 2012
- Modern Waitlist and Post-Transplant Survival in Combined Organ Transplant: Should Patients Listed for Heart-Kidney and Heart-Liver Transplant Be Upgraded to Status 1b at Listing?. American Journal of Transplantation. 95-95. 2012
- 128 Redo Sternotomy in Patients Undergoing Heart Transplantation: A Propensity-Matched Survival Analysis of the United Network for Organ Sharing Database. The Journal of Heart and Lung Transplantation. S52-S52. 2012
- 165 Analysis of over 1000 Patients Listed for Combined Heart-Kidney Transplant in the Modern Era. The Journal of Heart and Lung Transplantation. S64-S64. 2012
- 49 Five Years of Lung Transplantation Since the Implementation of the Lung Allocation Score: A Comparative Analysis of Patient Characteristics and Outcomes. The Journal of Heart and Lung Transplantation. S25-S26. 2012
- ROLE OF YB-1 ON GLIAL TUMORS AND ITS PROMISE AS A MOLECULAR TARGET. Neuro-Oncology. I28-I28. 2011
- TARGETING POLO-LIKE KINASE FOR THE TREATMENT OF BRAIN TUMORS AND ITS UNIQUE CAPACITY TO ELIMINATE CANCER STEM CELLS THROUGH Sox-2 INHIBITION. Neuro-Oncology. I9-I9. 2011
- Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain. Cancer Research. 2011
- Y-BOX BINDING PROTEIN-1 (YB-1) INHIBITION TRIGGERS DIFFERENTIATION OF NORMAL AND CANCER STEM CELLS FROM THE BRAIN. Neuro-Oncology. 13-13. 2011
- GLIOMATOSIS CEREBRI IN CHILDREN-A MULTIFACETED DISEASE. Pediatric Blood and Cancer. 856-857. 2010
- MANAGEMENT OF AN INTRACRANIAL MATURE TERATOMA RECURRING AS A GERMINOMA. Neuro-Oncology. II133-II133. 2010
- MEDULLOBLASTOMA OVER THREE DECADES IN A SINGLE INSTITUTION - WHAT HAVE WE ACHIEVED. Neuro-Oncology. II61-II61. 2010
- REGULATION OF BMI1 BY THE SHH PATHWAY IN HUMAN MEDULLOBLASTOMA BRAIN TUMOUR INITIATING CELLS. Neuro-Oncology. II3-II3. 2010
- PILOMYXOID ASTROCYTOMA IN TWO DIFFERENT AGE GROUPS. Neuro-Oncology. 650-650. 2009
- Identification of a cancer stem cell in human brain tumors. Neurosurgery. 487-488. 2003
journal articles
- TRSC-04 DE NOVO GTP SYNTHESIS IS A METABOLIC VULNERABILITY FOR THE INTERCEPTION OF BRAIN METASTASES. NOA. 6:i40-i40. 2024
- Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells. Nature Medicine. 2024
- National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection. Child's Nervous System. 40:1339-1347. 2024
- Abstract 5112: Discovery of nuclear envelope mislocalization in MYC-driven group 3 medulloblastoma. Cancer Research. 84:5112-5112. 2024
- Abstract 5238: uPAR as a novel immunotherapeutic target in recurrent glioblastoma. Cancer Research. 84:5238-5238. 2024
- Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma. Cancer Research. 84:5241-5241. 2024
- Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors. Cancer Research. 84:5846-5846. 2024
- Abstract 60: Functional mapping of glioblastoma recurrence reveals targetable dependencies in an axonal guidance pathway in highly invasive brain cancers. Cancer Research. 84:60-60. 2024
- 89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs. EJNMMI Research. 14:29. 2024
- Abstract IA004: Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies. Cancer Research. 84:IA004-IA004. 2024
- Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases. Clinical Cancer Research. 30:554-563. 2024
- Alkylating agents are possible inducers of glioblastoma and other brain tumors. Human and Experimental Toxicology. 43:9603271241256598. 2024
- P102: Systematic characterization of cancer ecosystem evolution. Genetics in Medicine Open. 2:100983-100983. 2024
- Risk factors for glioblastoma are shared by other brain tumor types. Human and Experimental Toxicology. 43:9603271241241796. 2024
- Abstract A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis. Molecular Cancer Therapeutics. 22:A109-A109. 2023
- Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma. Molecular Cancer Therapeutics. 22:A158-A158. 2023
- Abstract C053: BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis. Molecular Cancer Therapeutics. 22:C053-C053. 2023
- Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma. Molecular Cancer Therapeutics. 22:C082-C082. 2023
- Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Molecular Cancer Therapeutics. 22:C097-C097. 2023
- Protocol for mapping the metabolome and lipidome of medulloblastoma cells using liquid chromatography-mass spectrometry. STAR Protocols. 4:102736-102736. 2023
- EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 25:v225-v225. 2023
- Correction to: Dynamic profiling of medulloblastoma surfaceome. Acta Neuropathologica Communications. 11:169. 2023
- P02.16.B COMPENSATORY CROSS-TALK BETWEEN AUTOPHAGY AND GLYCOLYSIS REGULATES SENESCENCE AND STEMNESS IN HETEROGENEOUS GLIOBLASTOMA TUMOR SUBPOPULATIONS. Neuro-Oncology. 25:ii33-ii33. 2023
- P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 25:ii49-ii49. 2023
- P10.22.B COMBINATION OF ARTS MIMETICS WITH AUTOPHAGY INHIBITORS AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME APOPTOSIS RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology. 25:ii67-ii67. 2023
- PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED POST-TRANSLATIONAL MECHANISM REGULATING THE ABUNDANCE OF THE ‘UNDRUGGABLE’ ONCOPROTEIN C-MYC IN MEDULLOBLASTOMA. Neuro-Oncology. 25:ii1-ii2. 2023
- BSBM-09 IN VIVO CRISPR ACTIVATION SCREEN IDENTIFIES ß-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) AS A DRIVER OF NON-SMALL CELL LUNG CANCER BRAIN METASTASIS. NOA. 5:iii2-iii2. 2023
- SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS. NOA. 5:iii33-iii33. 2023
- SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE. NOA. 5:iii33-iii33. 2023
- SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA. NOA. 5:iii34-iii34. 2023
- AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA. NOA. 5:i6-i6. 2023
- GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS. NOA. 5:i1-i2. 2023
- INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES. NOA. 5:i2-i2. 2023
- ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER. NOA. 5:i3-i3. 2023
- UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA. NOA. 5:i10-i10. 2023
- Dynamic profiling of medulloblastoma surfaceome. Acta Neuropathologica Communications. 11:111. 2023
- Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathologica Communications. 11:110. 2023
- An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. Journal of Neuro-Oncology. 163:635-645. 2023
- Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma. Cell Reports Medicine. 4:101071-101071. 2023
- Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nature Communications. 14:2502. 2023
- A single center experience in the management of progressive juvenile pilocytic astrocytoma. Journal of Neurosurgical Sciences. 67:311-316. 2023
- Abstract 1154: Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. Cancer Research. 83:1154-1154. 2023
- Abstract 2474: Uncovering a new therapeutic vulnerability for preventing brain metastases. Cancer Research. 83:2474-2474. 2023
- Abstract 6028: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Research. 83:6028-6028. 2023
- External ventricular drainage in the management of pediatric patients with posterior fossa tumors and hydrocephalus: a retrospective cohort study. Child's Nervous System. 39:887-894. 2023
- Comparison of Two Drainage Systems on Chronic Subdural Hematoma Recurrence. Journal of Neurological Surgery. Part A: Central European Neurosurgery. 84:157-166. 2023
- An HLA-G/SPAG9/STAT3 axis promotes brain metastases. Proceedings of the National Academy of Sciences of the United States of America. 120:e2205247120. 2023
- Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nature Communications. 14:136. 2023
- Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nature Communications. 13:7506. 2022
- Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Cell. 40:1488-1502.e7. 2022
- The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers. Acta Neuropathologica. 144:1127-1142. 2022
- 2022 Canadian Surgery Forum Sept. 15–17, 202201. Operative classification of ventral abdominal hernias: new and practical classification02. Watchful waiting for large primary splenic cysts03. Transversus abdominis plane (TAP) blocks with and without dexamethasone in colorectal surgery04. What factors determine publication of resident research day projects?05. Characterization of near-infrared imaging and indocyanine green use amongst general surgeons06. Variation in opioid prescribing after outpatient breast surgery: Time for a streamlined approach?07. Trends in graduate degree types and research output for Canadian academic general surgeons08. Would you prefer to undergo breast-conserving therapy or a mastectomy for early breast cancer? Comparison of perceptions of general and plastic surgeons09. Lack of representation of women and BIPOC individuals in Canadian academic surgery10. Medical student interest and perspectives on pursuing surgical careers: a multicentre survey evaluating 5-year trends11. Difficult cholecystectomy with cholecystogastric fistula12. Surviving nonsurvivable injuries: patients who elude the “lethal” Abbreviated Injury Scale (AIS) score of six13. Gunshot wounds sustained during legal intervention v. those inflicted by civilians: a comparative analysis14. The impact of delayed time to first head CT on functional outcomes after blunt head trauma with moderately depressed GCS15. Contemporary utility of diagnostic peritoneal aspiration in trauma16. Impact of delayed time to first head CT in traumatic brain injury17. Radiologic predictors of in-hospital mortality after traumatic craniocervical dissociation18. Measurement properties of a patient-reported instrument to evaluate functional status after major surgery19. The safety of venous thromboembolism chemoprophylaxis use in endoscopic retrograde cholangiopancreatography20. Characterizing Canadian rural surgeons: trends over time and 10-year replacement needs21. Contextual interference for skills development and transfer in laparoscopic surgery: a randomized controlled trial22. Evaluating the accuracy and design of visual backgrounds in academic surgical journals23. Defining rural surgery in Canada24. Validity of video-based general and procedure-specific self-assessment tools for surgical trainees in laparoscopic cholecystectomy25. Examining the equity and diversity characteristics of academic general surgeons in Canada26. Video-based coaching for surgical residents: a systematic review and meta-analysis27. Very-low-energy diets prior to nonbariatric surgery: a systematic review and meta-analysis28. Factors associated with resident research success: a descriptive analysis of Canadian general surgery trainees29. Global surgery pilot curriculum in Canadian undergraduate medical education: a novel approach30. How useful is ultrasound in predicting surgical findings of “mild cholecystitis”?31. Implementing a colorectal surgery “virtual hospital”: description of a novel outpatient care pathway to advance surgical care32. Trends in training and workforce planning for Canadian pediatric surgeons: a 10-year model33. Patient perspectives on intraoperative blood transfusion: results of semistructured interviews with perioperative patients34. Understanding intraoperative transfusion decision-making variability: a qualitative study using the Theoretical Domains Framework35. Effectiveness of preoperative oscillating positive expiratory pressure (OPEP) therapy in reduction of postoperative respiratory morbidity in patients undergoing surgery: a systematic review37. Accuracy of point-of-care testing devices for hemoglobin in the operating room: a systematic review and meta-analysis38. Opioid-free analgesia after outpatient general surgery: a qualitative study focused on the perspectives of patients and clinicians involved in a pilot trial39. The impact of the COVID-19 pandemic on general surgery residency: an analysis of operative volumes by residents at a Canadian general surgery residency program40. Postoperative care protocols for elderly emergency surgical patients: a quality improvement initiative42. Adverse events following robotic compared to laparoscopic and open surgery: a population-based analysis43. Is accrual higher for patients randomized to pragmatic v. exploratory randomized clinical trials? A systematic review and meta-analysis44. Effect of preoperative proton-pump inhibitor use on postoperative infectious and renal complications after elective general surgery45. The early burden of COVID-19 in emergency general surgery care across Canada46. Laparoscopic subtotal cholecystectomy for the difficult gallbladder: evolution of technique at a single teaching hospital and retrospective review47. The demand for emergency general surgery in Canada: a public health crisis48. Attitudes of Canadian general surgery staff and residents toward point-of-care ultrasound49. Psychological impact of COVID-19 on Canadian surgical residents50. Validation of an artificial intelligence platform for the guidance of safe laparoscopic cholecystectomy51. Predictors of recurrent appendicitis after nonoperative management: a prospective cohort study52. The effect of the first wave of the COVID-19 pandemic on colorectal and hepatobiliary oncologic outcomes at a tertiary care centre53. Trends in training and workforce representation for Canadian general surgeons working in critical care: a descriptive study54. White presentation: teaching safe opioid prescription and opioid use disorder management in Canadian universities56. How bad is really bad, eh? Impact of the first wave of the COVID-19 pandemic on residents’ operative volume: the experience of a Canadian general surgery program57. Surgeon-specific encounters within a multidisciplinary care pathway: Is there a role for shared care models in surgery?59. A pan-Canadian analysis of approach to treatment for acute appendicitis60. Appendix neoplasm stratified by age: understanding the best treatment for appendicitis61. Predicting acute cholecystitis on final pathology to prioritize surgical urgency: an evaluation of the Tokyo criteria and development of a novel predictive score62. Obesity is an independent predictor of acute renal failure after surgery64. Validation of a clinical decision-making assessment tool in general surgery65. Moral distress in the provision of palliative care delivery for surgical patients in British Columbia: lessons learned from the perspectives of general surgeons66. Delays in presentation and severity of illness predict adverse surgical outcomes among patients transferred from rural Indigenous communities for acute care surgery67. Remote video-based suturing education with smartphones (REVISE): a randomized controlled trial68. Modified Delphi consensus on appropriate use of laboratory investigations in acute care surgery patients72. Impacts of inpatient food at a tertiary care centre on patient satisfaction, nutrition and planetary health73. Racial disparities in health outcomes for oncological surgery in Canada75. Risk of recurrent laryngeal nerve injury from thyroidectomy is lower when intraoperative nerve monitoring (IONM) is used: an analysis of 17 688 patients from the NSQIP database01. The impact of the COVID-19 pandemic on non-smallcell lung cancer pathologic stage and presentation02. Screening criteria evaluation for expansion in pulmonary neoplasias (screen)03. Robotic-assisted lobectomy for early-stage lung cancer provides better patient-reported quality of life than video-assisted lobectomy: early results of the RAVAL trial04. Breathe Anew: designing and testing the feasibility of a novel intervention for lung cancer survivorship05. Learning objectives for thoracic surgery: developing a national standard for undergraduate medical education06. Plasma cell-free DNA as a point-of-care well-being biomarker for early-stage non-small-cell lung cancer patients07. Sarcopenia determined by skeletal muscle index predicts overall survival, disease-free survival and postoperative complications in resectable esophageal cancer: a systematic review and meta-analysis08. The short- and long-term effects of open v. minimally invasive thymectomy in myasthenia gravis patients: a systematic review and meta-analysis09. Optimizing opioid prescribing practices following minimally invasive lung resections through a structured quality improvement process10. Effects of virtual postoperative postdischarge care in patients undergoing lung resection during the COVID-19 pandemic11. Initiating Ethiopia’s first minimally invasive surgery program: a novel approach for collaborations in global surgical education12. Patient outcomes following salvage lung cancer surgery after definitive chemotherapy or radiation13. Replacing chest X-rays after chest tube removal with clinical assessment in postoperative thoracic surgery patients14. Updating the practice of thoracic surgery in Canada: a survey of the Canadian Association of Thoracic Surgeons15. The impact of COVID-19 on the diagnosis and treatment of lung cancer16. Development of a prediction model for survival time in esophageal cancer patients treated with resection17. The development and validation of a mixed reality thoracic surgical anatomy atlas18. Routine placement of feeding tubes should be avoided in esophageal cancer patients undergoing surgery19. Nodal count is no different during robotic segmentectomy compared with robotic lobectomy20. Point-of-care ultrasound-guided percutaneous biopsy of solid masses in the thoracic outpatient clinic: a safe, high-yield procedure to accelerate tissue diagnosis for patients with advanced thoracic malignancy21. Sarcopenia and modified frailty index are not associated with adverse outcomes after esophagectomy for esophageal cancer: a retrospective cohort study22. Near-infrared-guided segmental resection for lung cancer: an analysis of the learning curve23. Routine use of feeding jejunostomy tubes in patients undergoing esophagectomy for esophageal malignancy is safe and associated with low complication rates01. Ghost ileostomy versus loop ileostomy following total mesorectal excision for rectal cancer: a systematic review and meta-analysis02. Analysis of 100 consecutive colorectal cancers presenting at a Canadian tertiary care centre: delayed diagnosis and advanced disease03. Clinical delays and comparative outcomes in younger and older adults with colorectal cancer: a systematic review04. Recurrence rates of rectal cancer after transanal total mesorectal excision (taTME): a systematic review and meta-analysis05. Transanal total mesorectal excision for abdominoperineal resection (taTME-APR) is associated with poor oncological outcomes in rectal cancer patients: a word of caution from a multicentric Canadian cohort study06. Association between survival and receipt of recommended and timely treatment in locally advanced rectal cancer: a population-based study07. Trends and the impact of incomplete preoperative staging in rectal cancer08. Postoperative outcomes after elective colorectal surgery in patients with cirrhosis09. Bowel stimulation before loop ileostomy closure to reduce postoperative ileus: a multicentre, single-blinded, randomized controlled trial10. Recurrence following perineal rectosigmoidectomy ( Altemeier) with levatorplasty: a systematic review and meta-analysis11. Nonmodifiable risk factors and receipt of surveillance investigations following treatment of rectal cancer12. Safety and effectiveness of endoscopic full-thickness resection for the management of colorectal lesions: a systematic review and meta-analysis13. Impact of preoperative carbohydrate loading before colectomy: a systematic review and meta-analysis of randomized controlled trials14. Statin therapy in patients undergoing short-course neoadjuvant radiotherapy for rectal cancer15. Feasibility of targeted lymphadenectomy during complete mesocolic excision for colon cancer using indocyanine green immunofluorescence lymphatic mapping16. Feasibility of expanding an ambulatory colectomy protocol: a retrospective analysis of early discharge following minimally invasive colectomy in an enhanced recovery pathway17. Impact of rectal cancer on bowel dysfunction before treatment and its relationship with post-treatment function18. Canadian cost–utility analysis of artificial-intelligence-assisted colonoscopy for adenoma detection in fecal immunochemical-based colorectal cancer screening19. A comparison of outcomes following intracorporeal and extracorporeal anastomotic techniques in laparoscopic right colectomies20. Assessment of metabolic signatures using desorption electrospray ionization mass spectrometry (DESI) and rapid evaporative ionization mass spectrometry (REIMS) of rectal cancer samples to assist in determining treatment response21. The association between hospital characteristics and minimally invasive rectal cancer surgery: a population-based study22. Cancer centre level designation and the impact on treatment and outcomes in those with rectal cancer: a population-based study23. Oncological outcomes after colorectal cancer in patients with liver cirrhosis: a systematic review and meta-analysis24. Optimal preoperative nutrition for penetrating Crohn disease: a systematic review and meta-analysis25. Lymph node ratio as a predictor of survival for colon cancer: a systematic review and meta-analysis26. Barriers and facilitators for use of new recommendations for optimal endoscopic localization of colorectal neoplasms according to gastroenterologists and surgeons27. Emergency colorectal surgery in patients with cirrhosis: a population-based descriptive study28. Local recurrence rates and associated risk factors after transanal endoscopic microsurgery for benign polyps and adenocarcinomas29. Bowel dysfunction impacts mental health after restorative proctectomy for rectal cancer30. Evolution of psychological morbidity following restorative proctectomy for rectal cancer: a systematic review and meta-analysis31. Frailty predicts LARS and quality of life in rectal cancer survivors after restorative proctectomy32. Low anterior resection syndrome in a reference North American population: prevalence and predictive factors33. The evolution of enhanced recovery: same day discharge after laparoscopic colectomy34. Effect of ERAS protocols on length of stay after colorectal surgery: an interrupted time series analysis35. Practice patterns and outcomes in individuals with cirrhosis and colorectal cancer: a population-based study36. Understanding the impact of bowel function on quality of life after rectal cancer surgery37. Right-sided colectomies for diverticulitis have worse outcomes compared with left-sided colectomies38. Symptom burden and time from symptom onset to cancer diagnosis in patients with early-onset colorectal cancer39. The impact of access to robotic rectal surgery at a tertiary care centre: a Canadian perspective40. Management of rectal neuroendocrine tumours by transanal endoscopic microsurgery41. The gut microbiota modulates colorectal anastomotic healing in patients undergoing surgery for colorectal cancer42. Is there added risk of complications for concomitant procedures during an ileocolic resection for Crohn disease?43. Cost of stoma-related hospital readmissions for rectal cancer patients following restorative proctectomy with a diverting loop ileostomy: a nationwide readmissions database analysis44. Older age associated with quality of rectal cancer care: an ACS-NSQIP database study45. Outcomes of patients undergoing elective bowel resection before and after implementation of an anemia screening and treatment program47. Loop ileostomy closure as a 23-hour stay procedure: a randomized controlled trial48. Extended duration perioperative thromboprophylaxis with low-molecular-weight heparin to improve disease-free survival following surgical resection of colorectal cancer: a multicentre randomized controlled trial (PERIOP-01 Trial)49. Three-stage versus modified 2-stage ileal pouch anal anastomosis: perioperative outcomes, function and quality of life50. Compliance with extended venous thromboembolism prophylaxis in rectal cancer51. Extended-duration venous thromboembolism prophylaxis after diversion in rectal cancer52. Financial and occupational impact of low anterior resection syndrome: a qualitative study53. Nonoperative management for rectal cancer: patient perspectives54. Trends in ileostomy-related emergency department visits for rectal cancer patients55. Long-term implications of treatment of fecal incontinence: a single Canadian centre’s retrospective cohort study: a 17-year follow-up56. Externally benchmarking colorectal resection outcomes in our province against the ACS NSQIP risk calculator: identifying opportunities for improvement57. Externally benchmarking our provincial colectomy outcomes against the ACS NSQIP using the Codman Score: to identify possible opportunities for improvement of outcomes58. Rural v. urban documentation of recommended practices for optimal endoscopic colorectal lesion localization01. Incidence of in-hospital opioid use and pain after inguinal hernia repair02. Ventral hernia repair following liver transplantation: outcome of repair techniques and risk factors for recurrence01. Impact of the COVID-19 pandemic on bariatric surgery in North America: a retrospective analysis of 834 647 patients02. Patient selection and 30-day outcomes of SADI-S compared to RYGB: a retrospective cohort study of 47 375 patients03. New persistent opioid use following bariatric surgery: a systematic review and pooled proportion meta-analysis04. Bariatric surgery should be offered to active-duty military personnel: a retrospective study of the Canadian Armed Forces experience05. Opioid prescribing practices and use following bariatric surgery: a systematic review and pooled summary of data06. Sacred sharing circles: urban Indigenous Manitobans’ experiences with bariatric surgery07. Gastrogastric hernia after laparoscopic gastric great curve plication: a video presentation08. Characterization of comorbidities predictive of bariatric surgery09. Efficacy of preoperative high-dose liraglutide in patients with superobesity10. The effect of linear stapled gastrojejunostomy size in Roux-en-Y gastric bypass11. Fragility of statistically significant outcomes in randomized trials comparing bariatric surgeries12. Weight loss outcomes for patients undergoing conversion to Roux-en-Y gastric bypass after sleeve gastrectomy13. Are long waiting lists for bariatric surgery detrimental to patients? A single-centre experience14. Does upper gastrointestinal swallow study after bariatric surgery lead to earlier detection of leak?15. Pharmaceutical utilization before and after bariatric surgery16. Same-day discharge Roux-en-Y gastric bypass at a Canadian bariatric centre: pathway implementation and early experiences17. Safety and efficiency of performing primary bariatric surgery at an ambulatory site of a tertiary care hospital: a 5-year experience18. Impact of psychiatric diagnosis on weight loss outcomes 3 years after bariatric surgery19. Ursodeoxycholic acid (UDCA) for prevention of gallstone disease after laparoscopic sleeve gastrectomy (LSG): an Atlantic Canada perspective20. Fecal microbial transplantation and fibre supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial01. Incidence, timing and outcomes of venous thromboembolism in patients undergoing surgery for esophagogastric cancer: a population-based cohort study04. Omission of axillary staging and survival in elderly women with early-stage breast cancer: a population-based cohort study05. Patients’ experiences receiving cancer surgery during the COVID-19 pandemic: a qualitative study06. Cancer surgery outcomes are better at high-volume centres07. Attitudes of Canadian colorectal cancer care providers toward liver transplantation for colorectal liver metastases: a national survey08. Quality of narrative central and lateral neck dissection reports for thyroid cancer treatment suggests need for a national standardized synoptic operative template09. Transoral endoscopic thyroidectomy vestibular approach (TOETVA): indications and technique10. Temporal trends in lymph node assessment as a quality indicator in colorectal cancer patients treated at a high-volume Canadian centre11. Molecular landscape of early-stage breast cancer with nodal metastasis12. Beta testing of a risk-stratified patient decision aid to facilitate shared decision making for postoperative extended thromboprophylaxis in patients undergoing major abdominal surgery for cancer13. Breast reconstruction use and impact on oncologic outcomes among inflammatory breast cancer patients: a systematic review14. Association between patient-reported symptoms and health care resource utilization: a first step to develop patient-centred value measures in cancer care15. Complications after colorectal liver metastases resection in Newfoundland and Labrador16. Why do patients with nonmetastatic primary retroperitoneal sarcoma not undergo resection?17. Loss ofFAM46Cexpression predicts inferior postresection survival and induces ion channelopathy in gastric adenocarcinoma18. Liver-directed therapy of neuroendocrine liver metastases19. Neoadjuvant pembrolizumab use in microsatellite instability high (MSI-H) rectal cancer: benefits of its use in lynch syndrome20. MOLLI for excision of nonpalpable breast lesions: a case series22. Patients awaiting mastectomy report increased depression, anxiety, and decreased quality of life compared with patients awaiting lumpectomy for treatment of breast cancer23. Is microscopic margin status important in retroperitoneal sarcoma (RPS) resection? A systematic review and meta-analysis24. Absence of benefit of routine surveillance in very-low-risk and low-risk gastric gastrointestinal stromal tumors25. Effect of intraoperative in-room specimen radiography on margin status in breast-conserving surgery26. Active surveillance for DCIS of the breast: qualitative interviews with patients and physicians01 Outcomes following extrahepatic and intraportal pancreatic islet transplantation: a comparative cohort study02. Cholang-funga-gitis03. Evaluating the effect of a low-calorie prehepatectomy diet on perioperative outcomes: a systematic review and meta-analysis04. Toxicity profiles of systemic therapy for advanced hepatocellular carcinoma: a systematic review to guide neoadjuvant trials05. Should cell salvage be used in liver resection and transplantation? A systematic review and meta-analysis06. The association between surgeon and hospital variation in use of laparoscopic liver resection and short-term outcomes07. Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection08. Impact of neoadjuvant chemotherapy on postoperative outcomes of patients undergoing hepatectomy for intrahepatic cholangiocarcinoma: ACS-NSQIP propensity-matched analysis09. The impact of prophylactic negative pressure wound therapy on surgical site infections in pancreatic resection: a systematic review and meta-analysis10. Does hepatic pedicle clamping increase the risk of colonic anastomotic leak after combined hepatectomy and colectomy? Analysis of the ACS NSQIP database11. Development of a culture process to grow a full-liver tissue substitute12. Liver transplantation for fibrolamellar hepatocellular carcinoma: an analysis of the European Liver Transplant Registry13. Arming beneficial viruses to treat pancreatic cancer14. Hepaticoduodenostomy versus hepaticojenunostomy for biliary reconstruction: a retrospective review of a single-centre experience15. Feasibility and safety of a “shared care” model in complex hepatopancreatobiliary surgery: a 5-year analysis of pancreaticoduodenectomy16. Laparoscopic v. open pancreaticoduodenectomy: initial institutional experience and NSQIP-matched analysis17. Laparoscopic spleen-preserving distal pancreatectomy: Why not do a Warshaw?18. The impact of COVID-19 on pancreaticoduodenectomy outcomes in a high-volume hepatopancreatobiliary centre19. Transitioning from open to minimally invasive pancreaticoduodenectomy: the learning curve factor in an academic centre20. Closed-incision negative-pressure wound therapy following pancreaticoduodenectomy for prevention of surgical site infections in high-risk patients21. Robotic Appleby procedure for recurrent pancreatic cancer22. The influence of viral hepatitis status on posthepatectomy complications in patients with hepatocellular carcinoma: a NSQIP analysis. Canadian Journal of Surgery. 65:S33-S111. 2022
- DDDR-03. DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. Neuro-Oncology. 24:vii98-vii99. 2022
- EPCO-07. NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA. Neuro-Oncology. 24:vii117-vii117. 2022
- EXTH-81. ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA. Neuro-Oncology. 24:vii228-vii228. 2022
- MODL-05. DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY. Neuro-Oncology. 24:vii291-vii292. 2022
- Derivation and culturing of neural stem cells from human embryonic brain tissue. STAR Protocols. 3:101628-101628. 2022
- BSCI-13 DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. NOA. 4:i3-i3. 2022
- BSCI-22 DETERMINING THE EFFECT OF NOVEL SMALL MOLECULE DRUGS AGAINST THE MIGRATION OF BRAIN METASTASIS INITIATING CELLS (BMICS). NOA. 4:i5-i5. 2022
- SYST-15 TARGETING AXONAL GUIDANCE WITH ANTI-ROBO1 CAR T CELLS: A NEW THERAPEUTIC STRATEGY FOR MALIGNANT BRAIN CANCER. NOA. 4:i24-i24. 2022
- Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures. Journal of Controlled Release. 348:386-396. 2022
- Functional discovery of targetable dependencies in recurrent glioblastoma 2022
- Abstract 3999: HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases. Cancer Research. 82:3999-3999. 2022
- Abstract 564: Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer. Cancer Research. 82:564-564. 2022
- Abstract 60: Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma. Cancer Research. 82:60-60. 2022
- Abstract 976: Interrogating the pre-metastastic gene signature to block brain metastases. Cancer Research. 82:976-976. 2022
- Characterization of an RNA binding protein interactome reveals the targetable post-transcriptional landscape of MYC-amplified medulloblastoma 2022
- Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma. Journal of Medicinal Chemistry. 65:3193-3217. 2022
- Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?. Neuro-Oncology. 24:226-228. 2022
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma 2022
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. Journal for ImmunoTherapy of Cancer. 10:e003289-e003289. 2022
- Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors. Frontiers in Immunology. 13:905768. 2022
- Reoperation in adult patients with recurrent glioblastoma: A matched cohort analysis. NOA. 4:vdac115. 2022
- The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues. Frontiers in Oncology. 12:815726. 2022
- The Role of a Longitudinal, Multidisciplinary Clinic in Building a Unique Research Collaborative. Frontiers in Oncology. 12:857699. 2022
- Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. Science Advances. 7:eabi5568. 2021
- In vitro evaluation of CAR-T cells in patient-derived glioblastoma models. STAR Protocols. 2:100920-100920. 2021
- EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. Neuro-Oncology. 23:vi175-vi175. 2021
- STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 23:vi21-vi21. 2021
- STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 23:vi22-vi22. 2021
- TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 23:vi215-vi215. 2021
- TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 23:vi218-vi218. 2021
- C.5 Musashi-1 is a master regulator of aberrant translation in MYC-amplified Group 3 medulloblastoma. Canadian Journal of Neurological Sciences. 48:S19-S19. 2021
- STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 23:vi21-vi21. 2021
- STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 23:vi22-vi22. 2021
- TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 23:vi215-vi215. 2021
- TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 23:vi218-vi218. 2021
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. NOA. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. NOA. 3:iii5-iii5. 2021
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. Neuro-Oncology Advances. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. Neuro-Oncology Advances. 3:iii5-iii5. 2021
- Advances in Immunotherapy for Adult Glioblastoma. Cancers. 13:3400-3400. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. NOA. 3:ii5-ii5. 2021
- Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. Cancer Research. 81:2874-2874. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. Neuro-Oncology Advances. 3:ii5-ii5. 2021
- Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma 2021
- EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 23:i10-i10. 2021
- EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. Neuro-Oncology. 23:i49-i49. 2021
- ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells. Journal of Personalized Medicine. 11:125-125. 2021
- Identification of five important genes to predict glioblastoma subtypes. NOA. 3:vdab144. 2021
- MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22:iii399-iii399. 2020
- A Patient-Derived Xenograft Model of Glioblastoma. STAR Protocols. 1:100179-100179. 2020
- Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis. STAR Protocols. 1:100124-100124. 2020
- MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22:iii399-iii399. 2020
- Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma. STAR Protocols. 1:100174-100174. 2020
- STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 22:ii196-ii196. 2020
- TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 22:ii213-ii213. 2020
- De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology. 3:645. 2020
- STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 22:ii196-ii196. 2020
- TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 22:ii213-ii213. 2020
- WNT: an unexpected tumor suppressor in medulloblastoma. Molecular and Cellular Oncology. 7:1834903-1834903. 2020
- RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status. Cancers. 12:3178-3178. 2020
- Development of a peptide-based delivery platform for targeting malignant brain tumors. Clinical Materials. 252:120105-120105. 2020
- Wnt activation as a therapeutic strategy in medulloblastoma. Nature Communications. 11:4323. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. NOA. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. NOA. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. NOA. 2:ii9-ii9. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology Advances. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. Neuro-Oncology Advances. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. Neuro-Oncology Advances. 2:ii9-ii9. 2020
- Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. 181:1329-1345.e24. 2020
- The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 26:832-844.e6. 2020
- A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 39:1590-1599. 2020
- Analysis of factors that influence neurosurgical length of hospital stay among newly diagnosed pediatric brain tumor patients. Pediatric Blood and Cancer. 67:e28041. 2020
- Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. Frontiers in Immunology. 11:599253. 2020
- The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. Frontiers in Oncology. 10:603738. 2020
- Predictive measures and outcomes of extent of resection in juvenile pilocytic astrocytoma. Journal of Clinical Neuroscience. 70:79-84. 2019
- STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 21:vi239-vi239. 2019
- STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 21:vi239-vi239. 2019
- Deciphering brain tumor heterogeneity, one cell at a time. Nature Medicine. 25:1474-1476. 2019
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. NOA. 1:i5-i5. 2019
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. Neuro-Oncology Advances. 1:i5-i5. 2019
- Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 572:67-73. 2019
- A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 36:51-67.e7. 2019
- Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. Journal of Neuro-Oncology. 143:417-428. 2019
- Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. Canadian Journal of Neurological Sciences. 46:403-414. 2019
- Regulation of the proline regulatory axis and autophagy modulates stemness in TP73/p73 deficient cancer stem-like cells. Autophagy. 15:934-936. 2019
- MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 21:ii108-ii108. 2019
- MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 21:ii112-ii113. 2019
- THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 21:ii117-ii117. 2019
- MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE. Neuro-Oncology. 21:ii105-ii105. 2019
- MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 21:ii108-ii108. 2019
- MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 21:ii112-ii113. 2019
- THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 21:ii117-ii117. 2019
- TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem–Like Cells in a Redox-Sensitive Manner. Clinical Cancer Research. 25:2001-2017. 2019
- Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry. 62:2651-2665. 2019
- A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations. Scientific Reports. 9:842. 2019
- EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. Methods in molecular biology (Clifton, N.J.). 1869:155-168. 2019
- Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis. World Neurosurgery. 120:e762-e775. 2018
- GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 20:vi107-vi107. 2018
- PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 20:vi208-vi208. 2018
- TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 20:vi273-vi273. 2018
- GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 20:vi107-vi107. 2018
- PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 20:vi208-vi208. 2018
- TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 20:vi273-vi273. 2018
- Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. Cell Death and Disease. 9:990. 2018
- Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. Cancer Research. 78:5023-5037. 2018
- Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. Cancer Research. 78:5124-5134. 2018
- Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology. 7:e1445459-e1445459. 2018
- MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 20:i119-i119. 2018
- MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 20:i133-i133. 2018
- Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs 2018
- 54 Genes preserving stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse. Canadian Journal of Neurological Sciences. 45:S13-S13. 2018
- MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 20:i119-i119. 2018
- MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 20:i133-i133. 2018
- P.033 Biopsy versus subtotal versus gross total resection in patients with low-grade glioma: a systematic review and meta-analysis. Canadian Journal of Neurological Sciences. 45:S24-S24. 2018
- P.044 Salvage therapy in recurrent pediatric medulloblastoma: A single centre experience. Canadian Journal of Neurological Sciences. 45:S27-S27. 2018
- Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma.. Journal of Clinical Oncology. 36:e14051-e14051. 2018
- Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. The Lancet. 391:1197-1204. 2018
- EMT: Mechanisms and therapeutic implications. Pharmacology and Therapeutics. 182:80-94. 2018
- Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and meta‐analysis. Clinical Obesity. 8:55-67. 2018
- Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival. Stem Cells International. 2018:1-19. 2018
- Erratum to: Introduction to Cancer Stem Cells: Past, Present, and Future. Methods in molecular biology (Clifton, N.J.). 1692:E1-E1. 2018
- Identification and Co-Targeting of EphA2/EphA3 Cancer Stem Cells in Recurrent Human Glioblastoma. SSRN Electronic Journal. 2018
- Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 553:101-105. 2018
- Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. Cell Reports. 21:2772-2784. 2017
- Evaluating overweight and obesity prevalence in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews. 6:43. 2017
- RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathologica. 134:923-940. 2017
- Brain tumor initiating cells: with great technology will come greater understanding. Future Neurology. 12:223-236. 2017
- CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi46-vi46. 2017
- CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi49-vi49. 2017
- CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 19:vi54-vi54. 2017
- EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 19:vi72-vi72. 2017
- IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 19:vi113-vi113. 2017
- STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 19:vi229-vi229. 2017
- STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:vi230-vi230. 2017
- STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi234-vi235. 2017
- TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19:vi254-vi254. 2017
- TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:vi255-vi255. 2017
- TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi255-vi255. 2017
- CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi46-vi46. 2017
- CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi49-vi49. 2017
- CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 19:vi54-vi54. 2017
- EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 19:vi72-vi72. 2017
- IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 19:vi113-vi113. 2017
- STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 19:vi229-vi229. 2017
- STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:vi230-vi230. 2017
- STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi234-vi235. 2017
- TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19:vi254-vi254. 2017
- TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:vi255-vi255. 2017
- TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi255-vi255. 2017
- Development of an Atypical Teratoid Rhabdoid Tumor in a Meningioma. International Journal of Surgical Pathology. 25:567-572. 2017
- The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. Obesity Reviews. 18:899-914. 2017
- Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology. 133:539-552. 2017
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Annals of Oncology. 28:1448-1456. 2017
- A.03 Analyses of surgical and MRI factors associated with cerebellar mutism. Canadian Journal of Neurological Sciences. 44:S9-S9. 2017
- MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:iv44-iv44. 2017
- TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 19:iv54-iv54. 2017
- TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:iv58-iv58. 2017
- MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:iv44-iv44. 2017
- TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 19:iv54-iv54. 2017
- TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:iv58-iv58. 2017
- Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study). Scientific Reports. 7:45078. 2017
- Atraumatic versus traumatic lumbar puncture needles: a systematic review and meta-analysis protocol. BMJ Open. 7:e014478-e014478. 2017
- The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study. Paediatrics and Child Health. 22:2-6. 2017
- CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 36:606-617. 2017
- Bmi1 – A Path to Targeting Cancer Stem Cells. European Oncology and Haematology. 13:147-147. 2017
- Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. Frontiers in Oncology. 7:220. 2017
- Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. Human Pathology. 59:125-130. 2017
- The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews. 5:101. 2016
- The identification of human pituitary adenoma-initiating cells. Acta Neuropathologica Communications. 4:125. 2016
- IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 18:vi98-vi98. 2016
- TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. Neuro-Oncology. 18:vi207-vi207. 2016
- TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. Neuro-Oncology. 18:vi211-vi212. 2016
- TMOD-37. CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 18:vi214-vi215. 2016
- Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population(s) in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S1-S1. 2016
- OS2 - 166 A Novel Model of Human Lung-to-Brain Metastasis and its Application to the Identification of Essential Metastatic Regulatory Genes. Canadian Journal of Neurological Sciences. 43:S2-S2. 2016
- OS4 - 161 Activated Wnt Signaling for the Therapeutic Targeting of Treatment-Refractory Medulloblastoma Stem Cells. Canadian Journal of Neurological Sciences. 43:S2-S3. 2016
- PS1 - 169 Discovering the Treatment Refractory BTIC Population in Group 3 Medulloblastoma through Therapy Adapted Patient-Derived Human Mouse Xenograft (PDX) Model. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS1 - 170 Bmi1 is a Therapeutic Target in Recurrent Childhood Medulloblastoma. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S13-S13. 2016
- PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells. Canadian Journal of Neurological Sciences. 43:S13-S14. 2016
- Subdural Hematoma Mimickers: A Systematic Review. World Neurosurgery. 93:73-80. 2016
- Abstract 2475: Bmi1 is a therapeutic target in recurrent medulloblastoma. Cancer Research. 76:2475-2475. 2016
- CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. Neuro-Oncology. 18:iii16.2-iii16. 2016
- EPI-04DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. Neuro-Oncology. 18:iii40.3-iii40. 2016
- MB-22ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 18:iii101.3-iii101. 2016
- QOS-21A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS. Neuro-Oncology. 18:iii149.4-iii149. 2016
- QOS-22IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?. Neuro-Oncology. 18:iii150.1-iii150. 2016
- Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. Neuro-Oncology. 18:350-360. 2016
- A novel stem cell culture model of recurrent glioblastoma. Journal of Neuro-Oncology. 126:57-67. 2016
- Development of a Patient-Derived Xenograft Model Using Brain Tumor Stem Cell Systems to Study Cancer. Methods in molecular biology (Clifton, N.J.). 1458:231-245. 2016
- Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells. Clinical Cancer Research. 21:5324-5337. 2015
- Reply to Letter. Annals of Surgery. 262:e114-e115. 2015
- Endovascular Thrombectomy for Acute Ischemic Stroke. Journal of the American Medical Association (JAMA). 314:1832-1832. 2015
- ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 17:v38.4-v39. 2015
- ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 17:v38-v39. 2015
- BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. Neuro-Oncology. 17:v51.5-v52. 2015
- BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. Neuro-Oncology. 17:v51-v52. 2015
- STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 17:v213.1-v213. 2015
- STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 6:27461-27477. 2015
- Exploring predictors of surgery and comparing operative treatment approaches for pediatric intracranial arachnoid cysts: a case series of 83 patients. Journal of Neurosurgery: Pediatrics. 16:275-282. 2015
- Letter to the Editor: Temporal evolution of medulloblastoma subgroups. Journal of Neurosurgery: Pediatrics. 16:349-351. 2015
- Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 34:3.3.1-3.3.13. 2015
- A Balanced Protocol for Return to School for Children and Youth Following Concussive Injury. Clinical Pediatrics. 54:783-792. 2015
- Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-Oncology. 17:868-881. 2015
- MB-14 * DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 17:iii22-iii22. 2015
- MB-15 * ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 17:iii23-iii23. 2015
- MB-15ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 17:iii23-iii23. 2015
- Cervical Spine Clearance in Obtunded Patients After Blunt Traumatic Injury. ACP journal club. 162:429-437. 2015
- Development of a Conservative Protocol to Return Children and Youth to Activity Following Concussive Injury. Clinical Pediatrics. 54:152-163. 2015
- MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. Stem Cells International. 2015:1-15. 2015
- The role of stem cells in pediatric central nervous system malignancies.. Advances in Experimental Medicine and Biology. 853:49-68. 2015
- Revealed: The spy who regulates neuroblastoma stem cells. Oncotarget. 5:11014-11016. 2014
- RM-06IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. Neuro-Oncology. 16:v187-v187. 2014
- SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. Neuro-Oncology. 16:v204-v204. 2014
- MEDULLOBLASTOMA. Neuro-Oncology. 16:i71-i96. 2014
- Brain Metastasis-Initiating Cells: Survival of the Fittest. International Journal of Molecular Sciences. 15:9117-9133. 2014
- Chronic Subdural Hematoma Management. Annals of Surgery. 259:449-457. 2014
- Generation of Murine Xenograft Models of Brain Tumors from Primary Human Tissue for In Vivo Analysis of the Brain Tumor-Initiating Cell. Methods in molecular biology (Clifton, N.J.). 1210:37-49. 2014
- Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. Cancer Research. 73:6734-6744. 2013
- Conflicting Diagnosis of Dermal Sinus Tract and Tethered Cord. Canadian Journal of Neurological Sciences. 40:889-891. 2013
- Is low-level laser therapy in relieving neck pain effective? Systematic review and meta-analysis. Rheumatology International. 33:2493-2501. 2013
- Medulloblastoma stem cells: Modeling tumor heterogeneity. Cancer Letters. 338:23-31. 2013
- FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells. Stem Cells. 31:1266-1277. 2013
- Expressional Analysis of GFP-Tagged Cells in an In Vivo Mouse Model of Giant Cell Tumor of Bone. Open Orthopaedics Journal. 7:109-113. 2013
- A Cancer Stem Cell Model for Studying Brain Metastases From Primary Lung Cancer. Journal of the National Cancer Institute. 105:551-562. 2013
- Evolution of Brain Tumor-Initiating Cell Research: In Pursuit of A Moving Target. Future Neurology. 8:1-3. 2013
- Investigating the Link between Molecular Subtypes of Glioblastoma, Epithelial-Mesenchymal Transition, and CD133 Cell Surface Protein. PLoS ONE. 8:e64169-e64169. 2013
- Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting. Journal of Visualized Experiments. 4111. 2012
- GBM secretome induces transient transformation of human neural precursor cells. Journal of Neuro-Oncology. 109:457-466. 2012
- Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells. 30:1064-1075. 2012
- Medulloblastoma stem cells: where development and cancer cross pathways. Pediatric Research. 71:516-522. 2012
- Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. Stem Cell Research. 8:141-153. 2012
- Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 31:187-199. 2012
- Abstracts from the 2011 BNOS Conference, June 29 – July 1, 2011, Homerton College, Cambridge. Neuro-Oncology. 13:ii1-ii14. 2011
- Combined Staged Endoscopic and Microsurgical Approach of a Third Ventricular Choroid Plexus Papilloma in an Infant. Minimally Invasive Neurosurgery. 54:264-267. 2011
- Endoscopic transnasal drainage of frontal epidural abscesses.. Journal of Otolaryngology - Head and Neck Surgery. 40:401-406. 2011
- YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research. 71:5569-5578. 2011
- Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. Journal of Trauma and Acute Care Surgery. 70:873-884. 2011
- Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 11:Unit3.3. 2009
- From Birth Till Death: Neurogenesis, Cell Cycle, and Neurodegeneration. Anatomical Record. 292:1953-1961. 2009
- Characterization of brain cancer stem cells: a mathematical approach. Cell Proliferation. 42:529-540. 2009
- An unexpected intracranial pressure crisis: infant brain abscess of unusual aetiology. Child's Nervous System. 25:377-381. 2009
- Brain Tumor Stem Cells: Identification and Concepts. Neurosurgery Clinics of North America. 18:31-38. 2007
- Identification of human brain tumour initiating cells. Nature. 432:396-401. 2004
- Cancer stem cells in nervous system tumors. Oncogene. 23:7267-7273. 2004
- Identification of a cancer stem cell in human brain tumors.. Cancer Research. 63:5821-5828. 2003
- Occipitocervical reconstruction with the Ohio Medical Instruments Loop: results of a multicenter evaluation in 30 cases. Journal of Neurosurgery. 98:239-246. 2003
- Cerebral salt wasting: Truths, fallacies, theories, and challenges. Critical Care Medicine. 30:2575-2579. 2002
- A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting. Journal of Neurosurgery. 95:420-424. 2001
- 807 Occipitocervical Reconstruction with the OMI Loop: Results of a Multicenter Trial in 50 Cases with Independent Review. Neurosurgery. 49:538-538. 2001
- 807 Occipitocervical Reconstruction with the OMI Loop: Results of a Multicenter Trial in 50 Cases with Independent Review. Neurosurgery. 49:538-538. 2001
- Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting. Journal of Visualized Experiments.
preprints
- National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection 2023